focus -WSS

focus

author：leisure time 2025-10-01 22:57:21 - browse：1

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Medicare drug price negotiation program allowed for now

entertainment

WSS

Ionis has late

Micronoma's microbiome cancer diagnostic approach under fire

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

STAT Virtual Event: How to Increase Diversity in Clinical Trials

5 important ways Henrietta Lacks changed medical science

Cigna to pay $172 million to settle Medicare Advantage fraud probe

focus

focus

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Micronoma's microbiome cancer diagnostic approach under fire

Tori Bowie and the unacceptable rates of Black maternal death

National panel will explore requiring free Covid tests

Jerome Adams on the need for new antivirals for Covid

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Mega Millions pot grows to $1.25 billion after no winner

Supreme Court strikes down use of affirmative action

How one patient went off dialysis — and others can too

knowledge

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Researchers use wearables data and AI to predict preterm birth risk

Wildfire pollution widens asthma inequities on Long Island

Biogen shutters digital health group, ends Apple study, in cost cutting move

Listen: Who gets the credit for GLP

EQRx, failed developer of low

explore

entertainment

entertainment

explore